Blog Posts

Lucjan Wyrwicz: Sometimes a Single Study can change a lot in Oncology

Lucjan Wyrwicz/LinkedIn

Jun 4, 2025, 10:22

Lucjan Wyrwicz: Sometimes a Single Study can change a lot in Oncology

Lucjan Wyrwicz, Head of Department, Dept. of Oncology and Radiotherapy at Maria Skłodowska-Curie Memorial Cancer Center, shared a post on LinkedIn:

“Sometimes a single study can change a lot in oncology. Matterhorn is an international study aimed to improve the outcomes in radical treatment of patients with the stomach cancer. Few extra infusions with minor side effects leads to major effect limiting greatly the chance of cancer recurrence. New agents are saving lives. Congratulations to Yelena Janjigian and the study team worldwide for this practice changing data. Great to be included as the co-author.

Btw: researchers from Maria Sklodowska-Curie National Research Institute of Oncology are included as co-authors in 3 of 5 abstracts presented at todays ASCO Presidential Session covering the most important and practice changing innovations shown during this years the most important oncology congress. Two thumbs up!”

Lucjan Wyrwicz highlighted the global impact of the Matterhorn trial, which demonstrates improved outcomes in radical stomach cancer treatment with minimal added toxicity. He also noted the involvement of his institution in several key ASCO 2025 presentations.

More posts featuring Lucjan Wyrwicz.

ASCO cancer Curie National Research Institute fight against cancer Global fight against cancer Lucjan Wyrwicz Maria Sklodowska MATTERHORN OncoDaily Oncology radiotherapy stomach cancer Yelena Janjigian

Vinay Prasad Rejoins FDA Days After Exit

New Paper Alert: Safety and Outcomes of T-DXd Retreatment After Grade 1 ILD Recovery

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech

Tyler Seibert: 10-year Results of FLAME Trial is Out Now